tetano
Editor, Senior Moderator
Virology
. 2024 May 23:596:110125.
doi: 10.1016/j.virol.2024.110125. Online ahead of print. A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge
Yuying Tian[SUP] 1 [/SUP], Zhuoya Deng[SUP] 2 [/SUP], Zhengran Chuai[SUP] 3 [/SUP], Cong Li[SUP] 1 [/SUP], Liangzheng Chang[SUP] 2 [/SUP], Fang Sun[SUP] 3 [/SUP], Rui Cao[SUP] 1 [/SUP], Hongyu Yu[SUP] 1 [/SUP], Ruixue Xiao[SUP] 1 [/SUP], Shuai Lu[SUP] 2 [/SUP], Yan Xu[SUP] 2 [/SUP], Penghui Yang[SUP] 4 [/SUP]
Affiliations
Influenza viruses present a significant threat to global health. The production of a universal vaccine is considered essential due to the ineffectiveness of current seasonal influenza vaccines against mutant strains. mRNA technology offers new prospects in vaccinology, with various candidates for different infectious diseases currently in development and testing phases. In this study, we encapsulated a universal influenza mRNA vaccine. The vaccine encoded influenza hemagglutinin (HA), nucleoprotein (NP), and three tandem repeats of matrix protein 2 (3M2e). Twice-vaccinated mice exhibited strong humoral and cell-mediated immune responses in vivo. Notably, these immune responses led to a significant reduction in viral load of the lungs in challenged mice, and also conferred protection against future wild-type H1N1, H3N2, or H5N1 influenza virus challenges. Our findings suggest that this mRNA-universal vaccine strategy for influenza virus may be instrumental in mitigating the impact of future influenza pandemics.
Keywords: Immunoprotection; Influenza viruses; Influenza viruses mRNA vaccine; mRNA vaccine.
. 2024 May 23:596:110125.
doi: 10.1016/j.virol.2024.110125. Online ahead of print. A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge
Yuying Tian[SUP] 1 [/SUP], Zhuoya Deng[SUP] 2 [/SUP], Zhengran Chuai[SUP] 3 [/SUP], Cong Li[SUP] 1 [/SUP], Liangzheng Chang[SUP] 2 [/SUP], Fang Sun[SUP] 3 [/SUP], Rui Cao[SUP] 1 [/SUP], Hongyu Yu[SUP] 1 [/SUP], Ruixue Xiao[SUP] 1 [/SUP], Shuai Lu[SUP] 2 [/SUP], Yan Xu[SUP] 2 [/SUP], Penghui Yang[SUP] 4 [/SUP]
Affiliations
- PMID: 38805804
- DOI: 10.1016/j.virol.2024.110125
Influenza viruses present a significant threat to global health. The production of a universal vaccine is considered essential due to the ineffectiveness of current seasonal influenza vaccines against mutant strains. mRNA technology offers new prospects in vaccinology, with various candidates for different infectious diseases currently in development and testing phases. In this study, we encapsulated a universal influenza mRNA vaccine. The vaccine encoded influenza hemagglutinin (HA), nucleoprotein (NP), and three tandem repeats of matrix protein 2 (3M2e). Twice-vaccinated mice exhibited strong humoral and cell-mediated immune responses in vivo. Notably, these immune responses led to a significant reduction in viral load of the lungs in challenged mice, and also conferred protection against future wild-type H1N1, H3N2, or H5N1 influenza virus challenges. Our findings suggest that this mRNA-universal vaccine strategy for influenza virus may be instrumental in mitigating the impact of future influenza pandemics.
Keywords: Immunoprotection; Influenza viruses; Influenza viruses mRNA vaccine; mRNA vaccine.